Compare · IRON vs NVO
IRON vs NVO
Side-by-side comparison of Disc Medicine Inc. (IRON) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IRON and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 68.1x IRON ($3.16B).
- Over the past year, IRON is up 37.9% and NVO is down 12.1% - IRON leads by 50.0 points.
- NVO has been more active in the news (9 items in the past 4 weeks vs 5 for IRON).
- NVO has more recent analyst coverage (25 ratings vs 20 for IRON).
- Company
- Disc Medicine Inc.
- Novo Nordisk A/S
- Price
- $82.51+1.75%
- $48.65+3.65%
- Market cap
- $3.16B
- $215.46B
- 1M return
- +10.59%
- -2.08%
- 1Y return
- +37.92%
- -12.07%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 5
- 9
- Recent ratings
- 20
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest IRON
- Chief Executive Officer Quisel John D exercised 33,000 shares at a strike of $13.50 and sold $2,611,982 worth of shares (33,000 units at $79.15) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Disc Medicine Inc.
- Chief Operating Officer Yu Jonathan Yen-Wen exercised 804 shares at a strike of $13.50 and sold $66,445 worth of shares (804 units at $82.64) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Legal Officer Khara Rahul exercised 5,000 shares at a strike of $14.69 and sold $400,000 worth of shares (5,000 units at $80.00) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Disc Medicine Inc.
- SEC Form 10-Q filed by Disc Medicine Inc.
- Disc Medicine Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update
- Chief Executive Officer Quisel John D exercised 33,000 shares at a strike of $10.68 and sold $2,473,780 worth of shares (33,000 units at $74.96) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Disc Medicine Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S